Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis

Hiroki Maruyama; Kaori Miyata; Mariko Mikame; Atsumi Taguchi; Chu Guili; Masaru Shimura; Kei Murayama; Takeshi Inoue; Saori Yamamoto; Koichiro Sugimura; Koichi Tamita; Toshihiro Kawasaki; Jun Kajihara; Akifumi Onishi; Hitoshi Sugiyama; Teiko Sakai; Ichijiro Murata; Takamasa Oda; Shigeru Toyoda; Kenichiro Hanawa; Takeo Fujimura; Shigehisa Ura; Mimiko Matsumura; Hideki Takano; Satoshi Yamashita; Gaku Matsukura; Ryushi Tazawa; Tsuyoshi Shiga; Mio Ebato; Hiroshi Satoh; Satoshi Ishii

doi:10.1038/s41436-019-0447-8

. 2019 Feb 6;21(5):1263. doi: 10.1038/s41436-019-0447-8

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis

Hiroki Maruyama ^1,^✉, Kaori Miyata ², Mariko Mikame ¹, Atsumi Taguchi ¹, Chu Guili ¹, Masaru Shimura ³, Kei Murayama ³, Takeshi Inoue ⁴, Saori Yamamoto ⁵, Koichiro Sugimura ⁵, Koichi Tamita ⁶, Toshihiro Kawasaki ⁶, Jun Kajihara ⁷, Akifumi Onishi ⁸, Hitoshi Sugiyama ⁸, Teiko Sakai ⁹, Ichijiro Murata ¹⁰, Takamasa Oda ¹¹, Shigeru Toyoda ¹², Kenichiro Hanawa ¹³, Takeo Fujimura ¹⁴, Shigehisa Ura ¹⁵, Mimiko Matsumura ¹⁶, Hideki Takano ¹⁶, Satoshi Yamashita ¹⁷, Gaku Matsukura ¹⁷, Ryushi Tazawa ¹⁸, Tsuyoshi Shiga ¹⁹, Mio Ebato ²⁰, Hiroshi Satoh ²¹, Satoshi Ishii ²²

¹Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

²Sanofi K.K., Sanofi Genzyme Medical Operations, Rare Disease Medical, Medical Science Liaison, Tokyo, Japan

³Department of Metabolism, Chiba Children’s Hospital, Chiba, Japan

⁴Department of Pediatrics, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan

⁵Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

⁶Nishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan

⁷Department of Cardiology, Fujinomiya City General Hospital, Fujinomiya, Japan

⁸Department of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan

⁹Sukoyaka Clinic, Gifu, Japan

¹⁰Department of Chronic Kidney Disease, Gifu University Graduate School of Medicine, Gifu, Japan

¹¹Yamaguchi Prefectural Grand Medical Center, Hofu, Japan

¹²Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan

¹³Department of Cardiology, Internal Medicine, Iwaki Kyoritsu General Hospital, Iwaki, Japan

¹⁴Department of Nephrology, Kashiwazaki General Hospital and Medical Center, Kashiwazaki, Japan

¹⁵Division of Neurology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan

¹⁶Department of Nephrology, Tokyo Teishin Hospital, Tokyo, Japan

¹⁷Department of Cardiology, Japanese Red Cross Hamamatsu Hospital, Hamamatsu, Japan

¹⁸Division of Medical Genetics, Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan

¹⁹Department of Cardiology, Tokyo Women’s Medical University, Tokyo, Japan

²⁰Division of Cardiology, Showa University Fujigaoka Hospital, Yokohama, Japan

²¹Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan

²²Glyco Pharma Corporation, Oita, Japan

^✉

Corresponding author.

PMCID: PMC7609257 PMID: 30728527

Correction to: Genetics in Medicine; 10.1038/gim.2018.31; published online 15 March 2018

The HTML version of this Article contained errors in Supplementary Figure S2 “Flowchart of the lyso-Gb3 screening and gene analysis in female patients”, which have been detailed in the associated Correction.

The upper square

Female with clinical symptoms suggestive of Fabry disease; “(n = 1036)” was revised to “(n = 1035).”

Neurology; “(n = 227)” was revised to “(n = 226).”

The second square from the top (left side)

Positive lyso-Gb3 screen; “(n = 15)” was revised to “(n = 14).”

Neurology; “(n = 2)” was revised to “(n = 1).”

The third square from the top (second square from the left)

Normal α-Gal A; “(n = 8)” was revised to “(n = 7).”

Neurology; “(n = 1)” was revised to “(n = 0).”

The fourth square from the top (second square from the left)

“Neurology (n = 1)” was deleted.

The revised Supplementary Information can be found as Supplementary Information associated with this Correction.

Supplementary information

Supplementary Information^{(1.4MB, pdf)}

SUPPLEMENTARY INFORMATION

The online version of this article (10.1038/s41436-019-0447-8) contains supplementary material, which is available to authorized users.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information^{(1.4MB, pdf)}

PERMALINK

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis

Hiroki Maruyama, MD, PhD

Kaori Miyata, BA

Mariko Mikame, BEd

Atsumi Taguchi, PhD

Chu Guili, MD, PhD

Masaru Shimura, MD

Kei Murayama, MD, PhD

Takeshi Inoue, MD, PhD

Saori Yamamoto, MD, PhD

Koichiro Sugimura, MD, PhD

Koichi Tamita, MD

Toshihiro Kawasaki, RDCS

Jun Kajihara, MD

Akifumi Onishi, MD

Hitoshi Sugiyama, MD, PhD

Teiko Sakai, MD

Ichijiro Murata, MD, PhD

Takamasa Oda, MD, PhD

Shigeru Toyoda, MD, PhD

Kenichiro Hanawa, MD, PhD

Takeo Fujimura, MD, PhD

Shigehisa Ura, MD

Mimiko Matsumura, MD

Hideki Takano, MD, PhD

Satoshi Yamashita, MD

Gaku Matsukura, MD

Ryushi Tazawa, MD, PhD

Tsuyoshi Shiga, MD, PhD

Mio Ebato, MD, PhD

Hiroshi Satoh, MD, PhD

Satoshi Ishii, PhD

Supplementary information

SUPPLEMENTARY INFORMATION

Associated Data

Supplementary Materials

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases